Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505154 | 0.81 | ESR2 (0.45) | ESR2ADORA1NR1H2GPR119USP2 | |
| SCHEMBL17942084 | 0.75 | GPR119 (0.39) | ESR2NR1H2GPR119USP2SMN1; SMN2 | |
| SCHEMBL19462690 | 0.74 | ADORA1 (0.43) | ESR2ADORA1NR1H2GPR119USP2 | |
| SCHEMBL28244949 | 0.74 | CTSK (0.38) | ESR2NR1H2GPR119ELANEBUB1 | |
| SCHEMBL31084282 | 0.73 | ADORA1 (0.33) | ESR2ADORA1NR1H2GPR119 | |
| SCHEMBL7420791 | 0.73 | ADORA1 (0.36) | ESR2ADORA1NR1H2GPR119USP2 | |
| SCHEMBL29234093 | 0.73 | ADORA1 (0.42) | ESR2ADORA1NR1H2GPR119USP2 | |
| SCHEMBL1199488 | 0.73 | GPR119 (0.39) | ESR2ADORA1NR1H2GPR119USP2 | |
| SCHEMBL28688256 | 0.72 | ESR2 (0.41) | ESR2NR1H2GPR119USP2SMN1; SMN2 | |
| SCHEMBL28311005 | 0.72 | NR1H2 (0.35) | NR1H2GPR119KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| WO-2012126084-A1 | HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE IΝ THE TREATMENT AND PREVENTION OF FUNGAL INFECTIONS | PHARMASCIENCE INC. (CA) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | ESR2 2465/4885ADORA1 2337/4885NR1H2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.